Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial - Ismael, G; Hegg, R; Muehlbauer, S (Lancet Oncology, 2012)
et al.